US Personalized Medicine Market 2025 – 2034

Reports Description

As per the US Personalized Medicine Market analysis conducted by the CMI team, the US personalized medicine market is expected to record a CAGR of 17.32% from 2025 to 2034. In 2025, the market size was USD 66.13 Billion. By 2034, the valuation is anticipated to reach USD 252.93 Billion.

Overview

Personalized medicine, also called precision medicine, implies customizing medical care as well as treatment plans as per the specific needs of every patient. The US personalized medicine market is growing on a significant note due to advancements in molecular biology, genomics, and computational technologies. The approach has been reported to be successful in some cancer treatments, in which identification of specified genetic mutations is likely to result in targeted therapies that are less toxic than conventional treatments.

As per the American Cancer Society's report, the year 2022 witnessed 609,360 cancer-related fatalities with around 1.9 million novel cases of cancer diagnosed. Plus, rising incidences of chronic ailments such as asthma, arthritis, chronic obstructive pulmonary disease, irritable bowel syndrome (IBD), and ulcerative colitis in the US are catalyzing the US personalized medicine market.

Key Trends & Drivers

• Advancements in Personalized Medicine

Shift from the single-gene testing to a clinical tool using molecular and genetic biomarkers us facilitating changes in the process of drug discovery. Pharmacogenomics is known for integrating patient and clinical data into the initial data sets, thereby accelerating path toward disease treatment.

The above-mentioned personalized approach is refurbishing management of several diseases inclusive of cancer, infectious diseases, neurological diseases, autoimmune diseases, gynecological conditions, and bladder dysfunction. Personalized medicine, through usage of epigenomics, genetics, and clinical insights, is keeping the cash registers ringing for the healthcare vertical on the whole.

• Increasing Government Initiatives and Funding

The R&D department of the US is moving fast owing to monetary support from commercial and public sectors, thereby opening probabilities for personalized healthcare. Extensive endeavors, at times inclusive of partnerships at the global level, are being made for identifying fundamental environmental and genetic components of several medical conditions. Businesses and research institutes concentrating on personalized medical techniques/technology are eligible to apply for subsidies and grants. Commercialization on the part of new services and goods is witnessing acceleration owing to the capital flow mentioned above, which is boosting the market further.

What's trending in the US Personalized Medicine Market?

Oncology continues to dominate the US personalized medicine market, which is an outcome of tailored diagnostics and treatments in cancer care.AI, advancements in epigenomics and genomics are catalyzing the innovation with respect to personalized medicine, thereby facilitating more accurate diagnostics followed by targeted therapies. Molecular imaging systems are also playing a vital role, especially in cancer monitoring and treatment.

To learn more about this report - request a sample report PDF

Key Threats

• Regulatory Challenges and Data Privacy Concerns

Personalized medicine asks for gathering and analyzing a substantial quantity of sensitive data inclusive of genetic data. As such, healthcare professionals and patients may hesitate owing to worries regarding security breaches, data privacy, and genetic information getting abused, which, in turn, may raise legal and moral concerns.

Furthermore, non-uniformity regarding regulatory frameworks may hamper the market. Access as well as acceptance on the part of the market could get impacted by approval as well as reimbursement procedures involved with personalized medicines, which are likely to increase the complexity as compared to traditional treatments.

Opportunities

Using AI and ML makes it possible to evaluate a huge chunk of patient data within no time. This, in turn, expedites the administration of focused and individualized therapies. Numerous personalized medicine applications make use of ML and AI on the basis of molecular and patient-specific genetic profiles. Incorporating AI/ML algorithms with personalized medicine enables resolution of complex problems in precision medical care by researchers, physicians, and practitioners.

AI and ML speed up the process of drug development, thereby helping in forecasting effectiveness of new medication and identifying probable therapeutic targets.

ML and AI are capable of identifying connections and patterns that could be missed out by the human researchers, which could result in a higher level of precision as far as diagnoses followed by potent therapies are concerned.

In January 2024, PYC Therapeutics announced that it had inked a partnership agreement such that it would be working with Google cloud and various other specialist partners for using AI to extend support development of new pharmaceuticals. PYC, known for using cutting-edge medical technologies such as RNA treatment, is into integration of AI platform of Google Cloud with its ML models.

Category Wise Insights

By Product

• Personalized Medicine Diagnostics

Personalized medicine diagnostics that include biomarker analysis and genomic testing let healthcare providers understand the patient's exclusive molecular and genetic profile, thereby leading to more precise diagnoses and selection of the therapies with fewer side-effects and a larger likelihood of efficacy. This is especially effective in oncology, wherein cancer treatment is being revolutionized by targeted therapies.

The other areas of application include cardiovascular diseases, infectious diseases, and central nervous system diseases, thereby widening scope as well as growth of the US personalized medicine market.

• Personalized Medicine Therapeutics

Personalized medicine therapeutics, which are informed by the patient's unique genetic make-up, facilitate selection of apt medication as well as dosage, thereby resulting in better treatment outcomes and minimal adverse effects. For instance, synthesis of Herceptin for HER2-positive breast cancer does illustrate the way a targeted therapy could be effective for a specified patient population (as per a National Institutes of Health (NIH) report).

With rapid technological advancements like next-generation sequencing, AI-enabled platforms and gene editing tools such as CRISPR are vital in order to analyze huge quantities of patient data and coming up with innovative personalized therapies, thereby driving market expansion.

• Personalized Nutrition and Wellness

Personalized nutrition does encourage health management by proactive means by customizing interventions to individual risk factors as well as needs, thereby resulting in enhanced long-term health outcomes by early disease aversion. Furthermore, integrating wearables, digital platforms, genetic testing, and AI-driven diagnostics allows planning for precise personalized nutrition and wellness, thereby expanding the US personalized medicine market. Also, emphasis on prevention and targeted interventions through personalized nutrition and wellness can aid in reducing severity and incidence of chronic diseases, thereby lowering healthcare costs in the long run.

By Application

• Oncology

Personalized medicine in oncology aims delivering the appropriate care to the right patient at the appropriate time, thereby resulting in various measurable improvements in outcomes coupled with reduction in costs of healthcare. This, in turn, results in higher level of patient satisfaction with rising demand for personalized care. It encompasses developing targeted therapies, gene-based therapies, and immunotherapies offering reduced toxicity and increased efficacy in comparison with conventional approaches.

• CNS

The rising prevalence of central nervous system (CNS) disorders such as Parkinson's disease, Alzheimer's, and depression does create a robust demand for more individualized and effective treatments, which is catered to by personalized medicine. Neuroimaging, genetic testing, and pharmacogenomics allow for deeper understanding of variations in the brain, thereby facilitating development of various personalized nanomedicines for CNS diseases.

• Immunology

The immune system's deeper comprehension has resulted to developing personalized immunotherapies such as CAR-T cell therapies and immune checkpoint inhibitors that are tailored to specified profile and immune response of an individual. Success on the part of immuno-oncology is a major catalyst, thereby shifting development of drug from wide approaches to the individualized strategies on the basis of complex interplay between immune system and cancer.

• Respiratory

Personalized medicine is revolutionizing treatment of cancer, especially non-small cell lung cancer (NSCLC) by the usage of targeted therapies on the basis of specific mutations of tumor such as ALK gene, thereby resulting in development of drugs such as crizotinib. Personalized medicine is getting applied across a broad range of respiratory diseases inclusive of asthma, interstitial lung diseases, pulmonary infections, COPD, and rare respiratory disorders.

• Liver

Advancements in liver modeling technologies, rise in understanding of complexities pertaining to liver disease, and demand for customized therapies for cirrhosis and hepatitis are accelerating the US personalized medicine market. Liver-related ailments do make liver-specific pharmacokinetic studies important for personalized medicine, thereby allowing for personalized drug selection as well as dosage adjustments for optimizing efficacy and minimizing adverse reactions, specifically in the patients suffering from liver diseases.

• Rheumatology

Rheumatology research is into identification of various biomarkers, specifically in rheumatoid arthritis, like genetic variants and anti-CCP2, which are capable of predicting disease progression, response to treatment, and potential side-effects. Such biomarkers facilitate more accurate selection of therapies, thereby averting ineffective treatments and cutting down on adverse reactions.

Technology

• Big Data Analytics

Big data analytics are capable of identifying genetic variations, lifestyle behaviors, and environmental factors that could contribute to health outcomes at an individual level, thereby allowing for preventive measures after early risk prediction. For instance - analysis of genomic data could reveal predispositions to some diseases such as cancer, thereby enabling proactive interventions and customized screening protocols. Big data also significantly reduces cost and time linked with drug discovery.

• Artificial Intelligence

AI-powered pharmacogenomics are restructuring clinical decision-making by making provisions for personalized treatment along with managed care. AI algorithms are capable of predicting drug efficacy, identifying biomarkers associated with response, and revealing optimal patient profiles for the drug therapies. AI also helps in designing smarter clinical trials by shortlisting patients who are more likely to benefit, thereby enhancing success rates and trial efficacy.

• Bioinformatics

Bioinformatics helps in identifying potential drug targets and designing drugs tailored toward specified genetic variants/disease subtypes by analyzing proteomic and genomic datasets. This is inclusive of prediction of drug metabolism as well as pharmacokinetic properties, thereby offering insights into efficacy of the potential drug candidates. Interpretation of complex genomic data through bioinformatics permits identification of susceptibilities of diseases and tailoring their treatments on the basis of individual genetic make-up.

• Gene Sequencing

DNA sequencing does apprise about genetic variations as well as mutations that are capable of predisposing individuals to some diseases or influencing their response to the treatment. This information is important for both - identifying individuals at a higher risk and diagnosing diseases, thereby allowing for preventive measures through early intervention. For instance - in oncology, having a patient's tumor sequenced is capable of identifying specified mutations that drive growth of cancer, thereby allowing the doctors to match them with the therapies that are targeted.

• Drug Discovery

Combining AI with personalized medicine in drug discovery is likely to revolutionize the way new treatments are developed. Personalized medicine comprehends the diseases better, thereby allowing the researchers to personalize the treatments for individuals. AI makes use of huge volumes of data (omics data) for speeding up drug discovery by locating new targets, enhancing the compounds, and simplifying the clinical trials with ML and algorithms. Combining such two approaches could accelerate discovery of the new treatments and make it simpler to utilize the existing drugs for novel purposes.

• Companion Diagnostics

Companion diagnostics (CDx) are important for expansion of the US personalized medicine market by facilitating targeted therapies and enhancing patient outcomes. They aid in identifying in patients who are likely of responding to a specific drug to a greater extent, thereby resulting in safer and more effective treatments. This approach does minimize the side-effects and also optimizes allocation of resources, thereby driving demand for companion diagnostics.

• Genetics

Genetics facilitates customized treatment strategies on the basis of genetic makeup of an individual. This encompasses usage of genomic sequencing for identifying specific variations of genes that impact disease susceptibility, treatment response, and drug metabolism. Understanding such genetic factors helps healthcare providers to select effective therapies for every patient, thereby optimizing outcomes of treatment and minimizing the adverse reactions.

• Liquid Biopsy

Liquid biopsies imply a minimially invasive way of detecting cancer-related biomarkers, monitoring treatment response, and identifying drug resistance.

Liquid biopsies do analyze circulating tumor DNA (ctDNA), circulating tumor cells (CTCs), and various other biomarkers in the bodily fluids such as blood. This lets doctors identify the specific genetic alterations and mutations in tumors, thereby guiding selection of the targeted therapies. For instance - Liquid biopsies, in oncology, could reveal mutations that could predict response of a patient to some drugs, thereby facilitating informed treatment decisions.

• Others (Predictive Modeling, Imaging)

Predictive modeling aids the healthcare providers shift to proactive from reactive personalized care. The rising volume and voluminous healthcare data do make predictive analysis necessary for stronger decision-making. Imaging facilitates early detection of diseases, thereby guiding the treatment decisions and monitoring the response to treatment.

By End-user

• Hospitals

Hospitals help in integration of genomic diagnostics with targeted therapies, thereby influencing development of new tools followed by treatments. They also contribute by helping with innovation and improving patient outcomes.

Hospital are at the forefront of adoption of personalized medicine approaches, thereby integrating targeted therapies and genomic diagnostics into the practices. This early adoption aids in driving development of novel diagnostic tools and therapeutic strategies, thereby dictating the future on the part of personalized medicine.

• Diagnostic Centers

Diagnostic centers provide necessary testing as well as analysis services that are important to tailor treatments to the individual patients. Such centers do utilize various advanced technologies such as imaging, genetic testing, and biomarker analysis for enabling personalized approaches toward healthcare.

Diagnostic centers do offer next-generation sequencing and the other genetic tests for identifying predisposition of an individual to some diseases, potential drug responses, and several other relevant genetic information.

• Research & Academic Institutes

Research & academic institutions explore novel technologies such as AI-powered diagnostics, gene editing, and organ-on-a-chip platforms. They superhead multi-omics (integrating proteomics, genomics, metabolomics, etc.) for understanding complexities of diseases and develop personalized strategies therein. They also refine computational tools needed for analyzing huge quantities of data generated in the personalized medicine research.

How is AI integration Transforming the US Personalized Medicine Market?

AI algorithms are capable of analyzing large quantities of data within a short time span. They help in the detection of subtle relationships and patterns that might get overlooked otherwise. AI has the ability of improving immunity.

Intelligent algorithms, by analyzing the patient's genetic predispositions, environment, and lifestyle choices, could identify the individuals at higher risk for rare and chronic diseases. This detection lets doctors implement interventions as well as preventive measures to enhance overall health. This iterative process leads to better outcomes for the patients over the period of time.

Report Scope

Key Developments

The US personalized medicine market is witnessing a significant organic and inorganic expansion. Some of the key developments include -

• In May 2025, the scientists based in Philadelphia officiated a successful treatment for one of the rare genetic disorders in a nine-month-old baby using personalized CRISPR gene editing therapy.

• In January 2024, The US state of California announced that it would witness establishment of precision medicine center as the outcome of collaboration amongst the city of Bakersfield, the Kern Venture Group, and BIOS Health. The facility is bound to operate as a central location for R&D and brain clinical trials that use BIOS' adaptive dosage technology.

• In March 2023, Seagen announced that Pfizer acquired it for USD 229 in cash per Seagen share, totaling to USD 43 Billion enterprise value.

To learn more about this report - request a sample report PDF

Leading Players

The US personalized medicine market is highly competitive, with a large number of service providers globally. Some of the key players in the market include:

• Illumina Inc.
• Precision Biologics
• Danaher Corporation (Cepheid Inc.)
• GE HealthCare
• Celera Diagnostics LLC
• Decode Genetics Inc.
• Exact Sciences Corporation
• IBM Corporation
• Exagen Inc.
• Biogen
• QIAGEN
• Genentech Inc.
• 23andMe Inc.
• Asuragen Inc.
• Others

These firms apply a plethora of strategies to enter the market, including innovations, mergers and acquisitions, as well as collaboration. The US personalized medicine market is shaped by the presence of diversified players that compete based on product innovation, vertical integration, and cost efficiency.